Caroline's Feed
Apr 24, 2014

Novartis sales miss forecast as readies overhaul

ZURICH, April 24 (Reuters) – Swiss drugmaker Novartis
posted a weaker-than-expected 1 percent rise in
quarterly sales, underscoring the pressures from generic
competition and tighter healthcare budgets that led it to
announce a radical business overhaul earlier this week.

On Tuesday, Novartis unveiled a series of deals worth over
$25 billion aimed at strengthening its cancer business and
exiting underperforming operations – part of a wider trend among
drugmakers to focus on their best assets.

Apr 22, 2014

Novartis and GSK trade assets as pharma industry reshapes

ZURICH/LONDON, April 22 (Reuters) – Novartis and
GlaxoSmithKline traded over $20 billion worth of assets
on Tuesday, aiming to bolster their best businesses and exit
weaker ones as the drugs industry reshapes to cope with
healthcare spending cuts and generic competition.

The deals, which include Novartis buying GSK’s cancer drugs
and GSK acquiring Novartis’ vaccines business, came hot on the
heels of a newspaper report that AstraZeneca had turned
down a $101 billion bid approach from Pfizer – a story
that sent shares across the sector surging.

Apr 22, 2014

Novartis reshapes business via deals with GSK and Lilly

ZURICH/LONDON (Reuters) – Swiss drugmaker Novartis announced a multi-billion dollar revamp on Tuesday, swapping assets with GlaxoSmithKline and selling its animal health arm in a bid to simplify its business and increase its focus on high-margin cancer medicines.

The overhaul is part of a major realignment in the global pharmaceuticals industry as it strives to cope with a clampdown in health spending by cash-strapped governments.

Apr 17, 2014

Actelion says year off to good start with new drug launch

ZURICH, April 17 (Reuters) – Actelion Ltd’s launch
of it new lung drug has got off to a good start and as a result
the Swiss firm might raise its earnings forecast at mid-year, it
said on Thursday after reporting a better than expected
first-quarter result.

Europe’s biggest biotech drugs company is banking on a
strong ramp-up in sales of the new drug, Opsumit, a treatment
for pulmonary arterial hypertension (PAH), to boost core
earnings in the low single-digit percentage range this year.

Apr 16, 2014

Syngenta sees bigger hit from weak emerging market currencies

ZURICH, April 16 (Reuters) – Syngenta AG, the
world’s largest maker of crop chemicals, expects weak emerging
markets currencies to have a bigger hit on full-year earnings
than previously assumed, it said on Wednesday, as it posted
higher first-quarter sales.

Adverse currency moves knocked 3 percent off quarterly
sales, which rose 2 percent to $4.7 billion, in line with the
average forecast in a Reuters poll.

Apr 15, 2014

New cancer drugs limit Roche first-quarter sales drop

ZURICH (Reuters) – A strong uptake of new cancer medicines helped Roche (ROG.VX: Quote, Profile, Research, Stock Buzz) to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

Roche Holding AG said currency movements, the loss of exclusivity on chemotherapy drug Xeloda and falling sales of hepatitis medicine Pegasys combined to pull sales down 1 percent.

Apr 10, 2014

French antitrust watchdog probes Roche and Novartis over eye drug

PARIS/ZURICH, April 10 (Reuters) – France’s competition
authority is investigating drugmakers Roche and
Novartis on suspicion they were involved in
anti-competitive practices in relation to eye disease
treatments, the companies said on Thursday.

This is the second time in as many months that the Swiss
drugmakers have faced regulatory scrutiny over treatments for
wet age-related macular degeneration (AMD)- a leading cause of
blindness among the elderly.

Apr 7, 2014

Holcim, Lafarge agree merger to create cement giant

PARIS/ZURICH (Reuters) – Switzerland’s Holcim (HOLN.VX: Quote, Profile, Research, Stock Buzz) unveiled a deal to buy France’s Lafarge (LAFP.PA: Quote, Profile, Research, Stock Buzz) on Monday to create the world’s biggest cement maker, with $44 billion of annual sales, and spark a raft of asset sales worldwide to steer it through antitrust rules.

The partners billed the cement, concrete and aggregates industry’s biggest ever tie-up as a merger of equals, under which Lafarge shareholders receive one Holcim share for every Lafarge held and Holcim investors end up with 53 percent of the group. The merged business will be based in Switzerland and listed in Zurich and Paris.

Apr 3, 2014

Credit Suisse increases provision for U.S. tax deal

ZURICH (Reuters) – Credit Suisse has increased the funds it has set aside to settle a U.S. tax dispute and avoid prosecution for helping wealthy Americans to hide cash from the taxman, raising the prospect it may be close to a settlement in the lengthy dispute.

Switzerland’s second-biggest bank also disclosed in its annual report on Thursday it had paid its Chief Executive Brady Dougan 9.8 million francs in 2013, up 26 percent from the previous year, a rise it said was justified by the bank’s performance over the period.

Mar 31, 2014

Mila sees big firms using web to outsource customer support

ZURICH (Reuters) – Mila, a Swiss peer-to-peer online marketplace for services ranging from IT support to furniture assembly, expects big European firms to turn to such platforms as a cheap way to improve their customer care.

Austere times and cheap mobile technology have helped kickstart the so-called sharing economy, in which individuals rent out their time and expertise – from lending power tools to making their cars available for hire.